EL7.AI
StocksMedium•2 November 2026•
4 min read

Coloplast Cuts Growth Target to 5-7%, Targets Mid-20s Profit Margin

Key Facts

1Coloplast cut its annual organic revenue growth target through 2030 to 5-7%, from the previous target of 7-8%.
2The company targets a long-term EBIT margin in the mid-20s at constant exchange rates.
3Coloplast expects organic growth of 5-7% and a margin of about 25% at constant exchange rates and before special items in fiscal 2026/27.
4The company targets a return on invested capital of about 20% in fiscal 2029/30.
5Organic revenue growth was 6% in the nine months ended June 30, 2026.

Coloplast has lowered its long-term financial ambitions, targeting annual organic revenue growth of 5% to 7% through 2030, compared with the range of 7% to 8% announced in September 2025. The company said in an announcement reported by Yahoo Finance that its revised plan also includes an EBIT margin in the mid-20s at constant exchange rates. Coloplast targets a return on invested capital of about 20% in fiscal 2029/30. The new targets place growth, profitability and returns on capital within a single framework for the coming period. The lower growth range reflects a revision to the assumptions underlying the previous plan.

For fiscal 2026/27, the company expects organic revenue growth of 5% to 7% and an EBIT margin of about 25% at constant exchange rates and before special items. This guidance combines a growth target with a profitability measure and specifies the basis for calculating the margin. The long-term margin target is in the mid-20s at constant exchange rates through 2030. The company has therefore provided near-term guidance for the coming fiscal year alongside financial ambitions extending to the end of the decade. A comparison between expected growth for a full year and results for the previous nine months compares two different periods.

Coloplast said its review of its ambitions reflects changes in the external environment, including changes to U.S. reimbursement for biologics, pricing pressures and inflation. The reimbursement impact is linked to the biologics market, which showed pressure on growth in the third quarter of fiscal 2025/26. Revenue in the segment was about 274 million Danish kroner in that quarter, while its organic growth fell 6%, with the company attributing the decline to the negative impact of the reimbursement change. This provides direct segment context for one of the factors the company cited in reviewing its targets. The company also included pricing pressures and inflation among the factors behind the revision.

The revised targets follow results for the nine months ended June 30, 2026, when Coloplast recorded organic revenue growth of 6% and a 5% increase in EBIT at constant exchange rates. At the time, the company kept its fiscal 2025/26 organic revenue growth forecast at 5% to 6%. The growth range targeted for fiscal 2026/27 is 5% to 7%, while the previous guidance for the current fiscal year was 5% to 6%. The interim results provide a view of performance through the end of June alongside the guidance the company announced for the following period, although the two periods are not equivalent. The previous financial ambition targeted compound annual growth of 7% to 8% over five years through fiscal 2029/30.

Coloplast’s previous plan assumed market growth of 4% to 5% through fiscal 2029/30, with no significant pricing impact. That assumption provides context for the move from the revenue growth target of 7% to 8% to the revised range of 5% to 7%. Alongside growth, the current plan includes a target EBIT margin in the mid-20s at constant exchange rates and a target return on invested capital of about 20% in fiscal 2029/30. The nine-month results reflect organic revenue growth and the increase in operating profit recorded through June 30, 2026, rather than a full fiscal-year result. The available picture therefore combines interim performance, guidance for the coming fiscal year and longer-term targets.

Coloplast set November 5, 2026, as the date for publishing its full-year 2025/26 financial statements. Those results will be the next milestone in the announced schedule, following the guidance the company previously maintained for organic revenue growth of 5% to 6% in the current fiscal year. The upcoming results cover the year before the 2026/27 guidance, while the revised ambitions extend through 2030. The company’s long-term framework includes revenue growth, profit margin and return on invested capital, measured over different time frames. The results are scheduled to be published on the date announced by the company.